_0001.png)
_0003.gif)
_0007.png)
_0006.gif)
_0005.png)
Management
_0025.png)
Dr. Marcus Furch
Chief Executive Officer (CEO)
Chief Executive Officer (CEO)
Dr. Robert Gieseler-
von der Crone
Chief Scientific Officer (CSO)
von der Crone
Chief Scientific Officer (CSO)
- Home
- About us
- Research and Development
- Publications
- Partnerships
- Media
- FAQ
- Careers
- Contact
Dr. Marcus Furch, Co-Founder and CEO
Chemist by training; received his PhD in the area of Biochemistry from the University of Heidelberg in 1999, followed by an Executive MBA from the Maastricht University Business School. During his scientific and academic career he worked as a research scientist in international and renowned laboratories in Germany (Max-Planck Institute for Medical Research, Heidelberg as well as Hannover Medical School), France (CNRS, Montpellier), Spain (University of the Basque Country in San Sebástian) and the United States (The Scripps Research Institute, La Jolla, California). As management consultant at Brazilian Kienbaum subsidy Böge Consultores in São Paulo he advised chemical and pharmaceutical companies entering Latin American markets. During five years in business development at Fresenius SE, the global player of pharmaceuticals and medical devices, he was involved in numerous M&A, in-licensing, and partnering transactions. While working with Nalucon in Heidelberg as interim manager and advisor to both companies and investors in the chemical and life-science industry, he joined the founders of RBT.
Chemist by training; received his PhD in the area of Biochemistry from the University of Heidelberg in 1999, followed by an Executive MBA from the Maastricht University Business School. During his scientific and academic career he worked as a research scientist in international and renowned laboratories in Germany (Max-Planck Institute for Medical Research, Heidelberg as well as Hannover Medical School), France (CNRS, Montpellier), Spain (University of the Basque Country in San Sebástian) and the United States (The Scripps Research Institute, La Jolla, California). As management consultant at Brazilian Kienbaum subsidy Böge Consultores in São Paulo he advised chemical and pharmaceutical companies entering Latin American markets. During five years in business development at Fresenius SE, the global player of pharmaceuticals and medical devices, he was involved in numerous M&A, in-licensing, and partnering transactions. While working with Nalucon in Heidelberg as interim manager and advisor to both companies and investors in the chemical and life-science industry, he joined the founders of RBT.
Dr. Robert Gieseler-von der Crone, Co-founder and CSO
Biologist by training; received his PhD in Immunology in 1991. When at Georg August University in Göttingen, he was among those elucidating the ontogeny of myeloid dendritic cells, and he co-developed the gold standard in-vitro differentiation protocol for these APCs. From 1989 to 1990, he worked with Dr. Scolaro in a joint HIV/AIDS research program by St. Vincent Medical Center and the University of Southern California Medical School in Los Angeles, USA. Subsequently, he did commissioned work for the Merck Frosst Centre for Therapeutic Research in Quebec, Canada, and then led preclinical research programs on solid organ transplantation, oncology, and autoimmunity at Georg August University, Göttingen, and the University of Essen Medical School in Essen, Germany. As of 2001, Dr. Gieseler worked for five years as Chief Scientist at a public non-profit research institute in Los Angeles together with Dr. Scolaro. With a team of scientists, their work provided the foundation for the proprietary technology developed at RBT; in parallel, he held a position as Adjunct Professor at the University of Florida, USA. Subsequently, he supervised the Northern Europe R&D division of Laboratorios LETI, S.L., Spain. As of 2007, he has been appointed as Research Coordinator on hepatitis C and other liver diseases at the University of Essen Medical School.
Biologist by training; received his PhD in Immunology in 1991. When at Georg August University in Göttingen, he was among those elucidating the ontogeny of myeloid dendritic cells, and he co-developed the gold standard in-vitro differentiation protocol for these APCs. From 1989 to 1990, he worked with Dr. Scolaro in a joint HIV/AIDS research program by St. Vincent Medical Center and the University of Southern California Medical School in Los Angeles, USA. Subsequently, he did commissioned work for the Merck Frosst Centre for Therapeutic Research in Quebec, Canada, and then led preclinical research programs on solid organ transplantation, oncology, and autoimmunity at Georg August University, Göttingen, and the University of Essen Medical School in Essen, Germany. As of 2001, Dr. Gieseler worked for five years as Chief Scientist at a public non-profit research institute in Los Angeles together with Dr. Scolaro. With a team of scientists, their work provided the foundation for the proprietary technology developed at RBT; in parallel, he held a position as Adjunct Professor at the University of Florida, USA. Subsequently, he supervised the Northern Europe R&D division of Laboratorios LETI, S.L., Spain. As of 2007, he has been appointed as Research Coordinator on hepatitis C and other liver diseases at the University of Essen Medical School.